Drug Trial Radar · NCT03070119
Long-Term Evaluation of BIIB067 (Tofersen)
Last checked: Nov 20, 2026Latest source record: Aug 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
139
Actual
Start
Mar 8, 2017
Primary completion
Aug 12, 2024
Study completion Aug 12, 2024
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- Collaborators
- Ionis Pharmaceuticals, Inc.
- First posted
- Mar 3, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to evaluate the long-term safety and tolerability of BIIB067 (tofersen) in participants with amyotrophic lateral sclerosis (ALS) and confirmed superoxide dismutase 1 (SOD1) mutation. The secondary objectives are to evaluate the pharmacokinetic (PK), pharmacodynamic (PD), biomarker effects, and efficacy of BIIB067 administered to participants with ALS and a confirmed SOD1 mutation.
Conditions
- ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation
Interventions
TofersenDrug
Participants will receive a loading dose regimen followed by maintenance dosing.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious AEs (TESAEs)Time frame: From first dose of the study drug in the current study up to end of follow-up period (up to Week 364)
Locations
30 sites in 9 countries. Site status is shown where the registry gives one.
Research Site
Phoenix, Arizona
Research Site
La Jolla, California
Research Site
San Francisco, California
Research Site
Jacksonville, Florida
Research Site
Miami, Florida
Research Site
Orlando, Florida
Research Site
Atlanta, Georgia
Research Site
Chicago, Illinois
Research Site
Baltimore, Maryland
Research Site
Boston, Massachusetts
Research Site
Rochester, Minnesota
Research Site
St Louis, Missouri
Research Site
Lincoln, Nebraska
Research Site
Cleveland, Ohio
Research Site
Portland, Oregon
Research Site
Knoxville, Tennessee
Research Site
Leuven, Belgium
Research Site
Calgary, Alberta, Canada
Research Site
Edmonton, Alberta, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Bispebjerg Hospital
Copenhagen, Denmark
Research Site
Clermont-Ferrand, Puy De Dome, France
Research Site
Ulm, Baden-Wurttemberg, Germany
Research Site
Torino, Italy
Research Site
Bunkyō City, Japan
Research Site
Kagoshima, Japan
Research Site
Shinjuku-ku, Japan
Research Site
Suita-shi, Japan
Research Site
Sheffield, South Yorkshire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.